RATIONALE: T-helper type 2 (Th2) inflammation, mediated by IL-4, IL-5, and IL-13, is considered the central molecular mechanism underlying asthma, and Th2 cytokines are emerging therapeutic targets. However, clinical studies increasingly suggest that asthma is heterogeneous. OBJECTIVES: To determine whether this clinical heterogeneity reflects heterogeneity in underlying molecular mechanisms related to Th2 inflammation. METHODS: Using microarray and polymerase chain reaction analyses of airway epithelial brushings from 42 patients with mild-to-moderate asthma and 28 healthy control subjects, we classified subjects with asthma based on high or low expression of IL-13-inducible genes. We then validated this classification and investigated its clinical implications through analyses of cytokine expression in bronchial biopsies, markers of inflammation and remodeling, responsiveness to inhaled corticosteroids, and reproducibility on repeat examination. MEASUREMENTS AND MAIN RESULTS: Gene expression analyses identified two evenly sized and distinct subgroups, "Th2-high" and "Th2-low" asthma (the latter indistinguishable from control subjects). These subgroups differed significantly in expression of IL-5 and IL-13 in bronchial biopsies and in airwayhyperresponsiveness, serum IgE, blood and airway eosinophilia, subepithelial fibrosis, and airway mucin gene expression (all P < 0.03). The lung function improvements expected with inhaled corticosteroids were restricted to Th2-high asthma, and Th2 markers were reproducible on repeat evaluation. CONCLUSIONS: Asthma can be divided into at least two distinct molecular phenotypes defined by degree of Th2 inflammation. Th2 cytokines are likely to be a relevant therapeutic target in only a subset of patients with asthma. Furthermore, current models do not adequately explain non-Th2-driven asthma, which represents a significant proportion of patients and responds poorly to current therapies.
RCT Entities:
RATIONALE: T-helper type 2 (Th2) inflammation, mediated by IL-4, IL-5, and IL-13, is considered the central molecular mechanism underlying asthma, and Th2 cytokines are emerging therapeutic targets. However, clinical studies increasingly suggest that asthma is heterogeneous. OBJECTIVES: To determine whether this clinical heterogeneity reflects heterogeneity in underlying molecular mechanisms related to Th2 inflammation. METHODS: Using microarray and polymerase chain reaction analyses of airway epithelial brushings from 42 patients with mild-to-moderate asthma and 28 healthy control subjects, we classified subjects with asthma based on high or low expression of IL-13-inducible genes. We then validated this classification and investigated its clinical implications through analyses of cytokine expression in bronchial biopsies, markers of inflammation and remodeling, responsiveness to inhaled corticosteroids, and reproducibility on repeat examination. MEASUREMENTS AND MAIN RESULTS: Gene expression analyses identified two evenly sized and distinct subgroups, "Th2-high" and "Th2-low" asthma (the latter indistinguishable from control subjects). These subgroups differed significantly in expression of IL-5 and IL-13 in bronchial biopsies and in airway hyperresponsiveness, serum IgE, blood and airway eosinophilia, subepithelial fibrosis, and airway mucin gene expression (all P < 0.03). The lung function improvements expected with inhaled corticosteroids were restricted to Th2-high asthma, and Th2 markers were reproducible on repeat evaluation. CONCLUSIONS:Asthma can be divided into at least two distinct molecular phenotypes defined by degree of Th2 inflammation. Th2 cytokines are likely to be a relevant therapeutic target in only a subset of patients with asthma. Furthermore, current models do not adequately explain non-Th2-driven asthma, which represents a significant proportion of patients and responds poorly to current therapies.
Authors: S E Wenzel; L B Schwartz; E L Langmack; J L Halliday; J B Trudeau; R L Gibbs; H W Chu Journal: Am J Respir Crit Care Med Date: 1999-09 Impact factor: 21.405
Authors: Ronald E Ferrando; Jens R Nyengaard; Steven R Hays; John V Fahy; Prescott G Woodruff Journal: J Allergy Clin Immunol Date: 2003-12 Impact factor: 10.793
Authors: Douglas A Kuperman; Christina C Lewis; Prescott G Woodruff; Madeleine W Rodriguez; Yee Hwa Yang; Gregory M Dolganov; John V Fahy; David J Erle Journal: J Allergy Clin Immunol Date: 2005-08 Impact factor: 10.793
Authors: M Humbert; S R Durham; P Kimmitt; N Powell; B Assoufi; R Pfister; G Menz; A B Kay; C J Corrigan Journal: J Allergy Clin Immunol Date: 1997-05 Impact factor: 10.793
Authors: Prescott G Woodruff; Laura L Koth; Yee Hwa Yang; Madeleine W Rodriguez; Silvio Favoreto; Gregory M Dolganov; Agnes C Paquet; David J Erle Journal: Am J Respir Crit Care Med Date: 2005-09-15 Impact factor: 21.405
Authors: Mike A Berry; Beverley Hargadon; Maria Shelley; Debbie Parker; Dominick E Shaw; Ruth H Green; Peter Bradding; Christopher E Brightling; Andrew J Wardlaw; Ian D Pavord Journal: N Engl J Med Date: 2006-02-16 Impact factor: 91.245
Authors: G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry Journal: Science Date: 1998-12-18 Impact factor: 47.728
Authors: Ryan H Dougherty; Sukhvinder S Sidhu; Kavita Raman; Margaret Solon; Owen D Solberg; George H Caughey; Prescott G Woodruff; John V Fahy Journal: J Allergy Clin Immunol Date: 2010-05 Impact factor: 10.793
Authors: Ravisankar A Ramadas; Marly I Roche; James J Moon; Thomas Ludwig; Ramnik J Xavier; Benjamin D Medoff Journal: J Immunol Date: 2011-11-09 Impact factor: 5.422
Authors: David M Center; David A Schwartz; Julian Solway; Dorothy Gail; Aaron D Laposky; Qing S Lin; Weiniu Gan Journal: Am J Respir Crit Care Med Date: 2012-05-31 Impact factor: 21.405
Authors: Yvonne J Huang; Craig E Nelson; Eoin L Brodie; Todd Z Desantis; Marshall S Baek; Jane Liu; Tanja Woyke; Martin Allgaier; Jim Bristow; Jeanine P Wiener-Kronish; E Rand Sutherland; Tonya S King; Nikolina Icitovic; Richard J Martin; William J Calhoun; Mario Castro; Loren C Denlinger; Emily Dimango; Monica Kraft; Stephen P Peters; Stephen I Wasserman; Michael E Wechsler; Homer A Boushey; Susan V Lynch Journal: J Allergy Clin Immunol Date: 2010-12-30 Impact factor: 10.793
Authors: Russell S Traister; Crystal E Uvalle; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2014-08-01 Impact factor: 10.793
Authors: Edward Zoratti; Suzanne Havstad; Ganesa Wegienka; Charlotte Nicholas; Kevin R Bobbitt; Kimberley J Woodcroft; Dennis R Ownby; Christine Cole Johnson Journal: Ann Allergy Asthma Immunol Date: 2014-05-05 Impact factor: 6.347